Ipca Laboratories Ltd. has announced the sale of its formulations manufacturing facility in Tarapur, Palghar, for ₹36.90 crore. The decision aligns with the company’s strategy to optimize manufacturing operations and reduce costs.
The facility, located at T-139, MIDC, Tarapur, was acquired in 2014 for ₹38.61 crore. The sale is being executed on a slump-sale basis to V. S. International Pvt. Ltd., a non-promoter entity engaged in pharmaceutical manufacturing. The deal is expected to be completed by June 30, 2025, pending necessary approvals. The sale will not impact Ipca’s business as production will be shifted to other facilities.
Additionally, Ipca Laboratories plans to acquire 100% of Unichem Laboratories Ltd., Ireland (Unichem Ireland), from Unichem Laboratories Ltd., India, for ₹4 crore. Unichem Ireland, incorporated in 2011, handles pharmaceutical registrations and distribution in Europe. This acquisition will strengthen Ipca’s European presence by allowing direct control over product registrations and market distribution.
Unichem Ireland had a turnover of ₹810.57 lakh in FY25 (until February) and recorded a profit of ₹108.60 lakh. The acquisition is based on a valuation report by GMJ & Co., Chartered Accountants and is expected to conclude by April 30, 2025.
